The convention nobody explains before handing over the vial
Insulin syringes are graduated in units on a convention that fixes 100 units to one millilitre. That convention says nothing about how much peptide is in a unit, and…
Practice Dispatch
What the new Italy guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The pharmacy regulator in Italy has issued counselling standards for initiation of GLP-1 receptor agonist therapy, specifying what must be covered at the point of supply: device technique, expected adverse effects, what to do about a missed dose, storage, sharps disposal, and — notably — what happens if treatment stops.
The titration document sets out three permissible responses to unresolved symptoms at a given dose: hold at the current dose for a further interval, return to the previous dose, or discontinue. It declines to specify a maximum hold duration, on the stated grounds that no evidence supports one.
The evidence base for most practical questions in this field is thin, and the better guidance documents say so explicitly rather than manufacturing a recommendation grade. The Journal reports the stated evidence quality alongside the recommendation, because a strong recommendation on low-quality evidence is a different object from a strong recommendation on high-quality evidence.
Nkosana Dube, pharmaceutical procurement adviser, noted who the document does not reach. "None of my patients who buy online will ever see this. That population is entirely outside the guidance system."
Our patient-notes department will cover the practical consequences in the next issue, including what the change means for someone scheduled for an elective procedure.
Related coverage
Portugal declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Ireland pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
The eighteenth month, and the conversation that should have happened in the third
What the trials measured was continuation against withdrawal. What patients want to know is continuation at a lower dose, and that study has largely not been done.
What we would need to randomise to answer this properly
One randomised trial has combined a GLP-1 receptor agonist with supervised exercise. Its result is the single most useful piece of evidence in this area.
What the new Germany guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.